Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase EARLY_PHASE1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Sarcoma, Ewing 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 1268Specimen Handling 871Carboplatin 831Magnetic Resonance Spectroscopy 805Cyclophosphamide 802Cisplatin 728Nivolumab 658Paclitaxel 630Radiotherapy 573Gemcitabine 571Biopsy 529Bevacizumab 476Dexamethasone 440fludarabine 406Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 358Fluorouracil 355atezolizumab 344durvalumab 333Rituximab 332Doxorubicin 317Radiosurgery 309Pemetrexed 306Drug Therapy 302Ipilimumab 294Standard of Care 293Etoposide 284Radiation 281

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × romiplostim × 1 year × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

NCT07048249 2026-03-18

Single Arm Romiplostim to Prevent CIT

Children's Hospital Medical Center, Cincinnati

Phase EARLY_PHASE1 Recruiting
26 enrolled
Sarcoma

Sarcoma, Ewing

NCT03362177 2026-02-11

RECITE

Amgen

Phase 3 Completed
165 enrolled 22 charts
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡